Switch theme
Sign up to access all valuation multiples
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
2011
157
LTM Revenue $6.5M
LTM EBITDA -$85.1M
$291M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Absci has a last 12-month revenue of $6.5M and a last 12-month EBITDA of -$85.1M.
In the most recent fiscal year, Absci achieved revenue of $4.5M and an EBITDA of -$89.1M.
Absci expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Absci valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.7M | $4.5M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$95.5M | -$89.1M | XXX | XXX | XXX |
| EBITDA Margin | -1669% | -1965% | XXX | XXX | XXX |
| Net Profit | -$105M | -$111M | XXX | XXX | XXX |
| Net Margin | -1835% | -2439% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Absci's stock price is $3.
Absci has current market cap of $394M, and EV of $291M.
See Absci trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $291M | $394M | XXX | XXX | XXX | XXX | $-0.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Absci has market cap of $394M and EV of $291M.
Absci's trades at 44.7x LTM EV/Revenue multiple, and -3.4x LTM EBITDA.
Analysts estimate Absci's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Absci and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $291M | XXX | XXX | XXX |
| EV/Revenue | 64.2x | XXX | XXX | XXX |
| EV/EBITDA | -3.3x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAbsci's NTM/LTM revenue growth is 203%
Absci's revenue per employee for the last fiscal year averaged $29K, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Absci's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Absci's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Absci and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -21% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1965% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1761% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $29K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1408% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2502% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| NetraMark | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Bullfrog AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Immuneering | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Absci acquired XXX companies to date.
Last acquisition by Absci was XXXXXXXX, XXXXX XXXXX XXXXXX . Absci acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Absci founded? | Absci was founded in 2011. |
| Where is Absci headquartered? | Absci is headquartered in United States of America. |
| How many employees does Absci have? | As of today, Absci has 157 employees. |
| Who is the CEO of Absci? | Absci's CEO is Mr. Sean McClain. |
| Is Absci publicy listed? | Yes, Absci is a public company listed on NAS. |
| What is the stock symbol of Absci? | Absci trades under ABSI ticker. |
| When did Absci go public? | Absci went public in 2021. |
| Who are competitors of Absci? | Similar companies to Absci include e.g. Benevolent AI, NetraMark, SyntekaBio, Bullfrog AI. |
| What is the current market cap of Absci? | Absci's current market cap is $394M |
| What is the current revenue of Absci? | Absci's last 12-month revenue is $6.5M. |
| What is the current EBITDA of Absci? | Absci's last 12-month EBITDA is -$85.1M. |
| What is the current EV/Revenue multiple of Absci? | Current revenue multiple of Absci is 44.7x. |
| What is the current EV/EBITDA multiple of Absci? | Current EBITDA multiple of Absci is -3.4x. |
| What is the current revenue growth of Absci? | Absci revenue growth between 2023 and 2024 was -21%. |
| Is Absci profitable? | Yes, Absci is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
